{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:02:49Z","timestamp":1780675369208,"version":"3.54.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.vaccine.2024.01.076","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T03:18:43Z","timestamp":1707448723000},"page":"1582-1592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0819-7891","authenticated-orcid":false,"given":"Aria","family":"Aminzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk","family":"Hilgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Paul Platenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9315-007X","authenticated-orcid":false,"given":"Micka\u00ebl","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Cauty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Barc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0672-466X","authenticated-orcid":false,"given":"Ren\u00e9","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.01.076_b0005","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile Infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.076_b0010","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States; 2019. doi: 10.15620\/cdc:82532.","DOI":"10.15620\/cdc:82532"},{"key":"10.1016\/j.vaccine.2024.01.076_b0015","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(14)70991-0","article-title":"Underdiagnosis of Clostridium difficile across Europe: The European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID)","volume":"14","author":"Davies","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.076_b0020","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1469-0691.2007.01824.x","article-title":"Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates","volume":"13","author":"Barbut","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2024.01.076_b0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(10)61266-4","article-title":"Clostridium difficile infection in Europe: a hospital-based survey","volume":"377","author":"Bauer","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.01.076_b0030","doi-asserted-by":"crossref","first-page":"e0176797","DOI":"10.1371\/journal.pone.0176797","article-title":"The emergence of Clostridium difficile infection in Asia: a systematic review and meta-analysis of incidence and impact","volume":"12","author":"Borren","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.01.076_b0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1079\/AHR200492","article-title":"The emergence of Clostridium difficile as a pathogen of food animals","volume":"5","author":"Songer","year":"2004","journal-title":"Anim Health Res Rev"},{"key":"10.1016\/j.vaccine.2024.01.076_b0040","article-title":"Global burden of Clostridium difficile infections: a systematic review and meta-analysis","volume":"9","author":"Balsells","year":"2019","journal-title":"J Glob Health"},{"key":"10.1016\/j.vaccine.2024.01.076_b0045","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-016-1786-6","article-title":"Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.076_b0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-micro-090816-093458","article-title":"Clostridium difficile toxin biology","volume":"71","author":"Aktories","year":"2017","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.vaccine.2024.01.076_b0055","first-page":"e53597","article-title":"High-resolution structure of native toxin A from Clostridioides difficile","author":"Aminzadeh","year":"2021","journal-title":"EMBO Rep"},{"key":"10.1016\/j.vaccine.2024.01.076_b0060","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/femsre\/fux048","article-title":"The role of toxins in Clostridium difficile infection","volume":"41","author":"Chandrasekaran","year":"2017","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2024.01.076_b0065","doi-asserted-by":"crossref","first-page":"13932","DOI":"10.1074\/jbc.270.23.13932","article-title":"The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins","volume":"270","author":"Just","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2024.01.076_b0070","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/375500a0","article-title":"Glucosylation of Rho proteins by Clostridium difficile toxin B","volume":"375","author":"Just","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.01.076_b0075","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1021\/bi972592c","article-title":"Glucosylation and ADP ribosylation of Rho proteins: effects on nucleotide binding, GTPase activity, and effector coupling","volume":"37","author":"Sehr","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.vaccine.2024.01.076_b0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.18.2.247-263.2005","article-title":"Clostridium difficile toxins: mechanism of action and role in disease","volume":"18","author":"Voth","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2024.01.076_b0085","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1086\/344729","article-title":"Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells","volume":"186","author":"Brito","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.076_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.1.1.1","article-title":"Clostridium difficile: its disease and toxins","volume":"1","author":"Lyerly","year":"1988","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2024.01.076_b0095","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1128\/iai.62.2.384-389.1994","article-title":"Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection","volume":"62","author":"Warny","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2024.01.076_b0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(00)03592-3","article-title":"Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea","volume":"357","author":"Kyne","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.01.076_b0105","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.vaccine.2003.11.030","article-title":"Active and passive immunization against Clostridium difficile diarrhea and colitis","volume":"22","author":"Giannasca","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.076_b0110","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/nature07822","article-title":"Toxin B is essential for virulence of Clostridium difficile","volume":"458","author":"Lyras","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.01.076_b0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nature09397","article-title":"The role of toxin A and toxin B in Clostridium difficile infection","volume":"467","author":"Kuehne","year":"2010","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.076_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.00551-15","article-title":"Defining the roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections","volume":"6","author":"Carter","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2024.01.076_b0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.anaerobe.2016.07.001","article-title":"Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors","volume":"41","author":"von Eichel-Streiber","year":"2016","journal-title":"Anaerobe"},{"key":"10.1016\/j.vaccine.2024.01.076_b0130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijid.2006.04.003","article-title":"Toxin A-negative, toxin B-positive Clostridium difficile","volume":"11","author":"Drudy","year":"2007","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.076_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/fmb.14.115","article-title":"Emergence of toxin A-negative, toxin B-positive Clostridium difficile strains: epidemiological and clinical considerations","volume":"10","author":"King","year":"2015","journal-title":"Future Microbiol"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.076_b0140","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1128\/IAI.68.10.5480-5487.2000","article-title":"Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease","volume":"68","author":"Barbieri","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2024.01.076_b0145","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1172\/JCI117885","article-title":"Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro","volume":"95","author":"Riegler","year":"1995","journal-title":"J Clin Investig"},{"key":"10.1016\/j.vaccine.2024.01.076_b0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for preventing recurrent Clostridium difficile infections","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.076_b0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41426-017-0019-4","article-title":"Advances in the diagnosis and treatment of Clostridium difficile infections review-article","volume":"7","author":"Peng","year":"2018","journal-title":"Emerging Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.01.076_b0160","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1053\/j.gastro.2008.12.070","article-title":"Treatment of Clostridium difficile-associated disease","volume":"136","author":"Leffler","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2024.01.076_b0165","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jinf.2009.03.010","article-title":"Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes","volume":"58","author":"Johnson","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2024.01.076_b0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/dkm113","article-title":"Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model","volume":"60","author":"Freeman","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.vaccine.2024.01.076_b0175","doi-asserted-by":"crossref","DOI":"10.2807\/ese.14.34.19316-en","article-title":"Struggling with recurrent Clostridium difficile infections: is donor faeces the solution?","volume":"14","author":"van Nood","year":"2009","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2024.01.076_b0180","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/cid\/cir632","article-title":"Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection","volume":"53","author":"Gough","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.076_b0185","article-title":"Regulation, risk and safety of Faecal Microbiota Transplant","volume":"2","author":"Merrick","year":"2020","journal-title":"Infect Prev Pract"},{"key":"10.1016\/j.vaccine.2024.01.076_b0190","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1099\/mic.0.066712-0","article-title":"A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile","volume":"159","author":"Donald","year":"2013","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2024.01.076_b0195","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1099\/jmm.0.056796-0","article-title":"Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters","volume":"62","author":"Anosova","year":"2013","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2024.01.076_b0200","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1016\/j.vaccine.2012.01.056","article-title":"Clostridium difficile: development of a novel candidate vaccine","volume":"30","author":"Foglia","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.076_b0205","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2004.11.004","article-title":"Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea","volume":"128","author":"Sougioultzis","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2024.01.076_b0210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.freeradbiomed.2020.08.021","article-title":"Detoxification of toxin A and toxin B by copper ion-catalyzed oxidation in production of a toxoid-based vaccine against Clostridioides difficile","volume":"160","author":"Aminzadeh","year":"2020","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.vaccine.2024.01.076_b0215","unstructured":"ClinicalTrials.gov Identifier: NCT02316470. Available online: ClinicalTrials.gov (accessed on 26 March 2021); n.d."},{"key":"10.1016\/j.vaccine.2024.01.076_b0220","unstructured":"ClinicalTrials.gov Identifier: NCT03918629. Available online: ClinicalTrials.gov (accessed on 26 March 2021); n.d."},{"key":"10.1016\/j.vaccine.2024.01.076_b0225","unstructured":"ClinicalTrials.gov Identifier: NCT04026009. Available online: ClinicalTrials.gov (accessed on 29 November 2021); n.d."},{"key":"10.1016\/j.vaccine.2024.01.076_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0157970","article-title":"Novel Clostridium difficile anti- Toxin (TcdA and TcdB) humanized monoclonal antibodies demonstrate in vitro neutralization across a broad spectrum of clinical strains and in vivo potency in a hamster spore challenge model","volume":"11","author":"Qiu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.01.076_b0235","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/infdis\/jis416","article-title":"Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies","volume":"206","author":"Marozsan","year":"2012","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.076_b0240","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.vaccine.2006.12.033","article-title":"Investigation of the detoxification mechanism of formaldehyde-treated tetanus toxin","volume":"25","author":"Thaysen-Andersen","year":"2007","journal-title":"Vaccine"},{"issue":"4426","key":"10.1016\/j.vaccine.2024.01.076_b0245","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/174405a0","article-title":"Detoxification of diphtheria toxin with formaldehyde mixed with an amino-acid","volume":"174","author":"Neum\u00fcller","year":"1954","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.076_b0250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0092-1157(87)90020-5","article-title":"The effects of different inactivating agents on the potency, toxicity and stability of pertussis vaccine","volume":"15","author":"Gupta","year":"1987","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2024.01.076_b0255","unstructured":"FDA, Vaccines licensed for use in the United States, 2019. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states; n.d."},{"key":"10.1016\/j.vaccine.2024.01.076_b0260","first-page":"252","article-title":"Detecting and preventing reversion to toxicity for a formaldehyde-treated C. difficile toxin B mutant","volume":"33","author":"Thiriot","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2024.01.076_b0265","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.xphs.2016.04.017","article-title":"Production and characterization of chemically inactivated genetically engineered Clostridium difficile toxoids","volume":"105","author":"Vidunas","year":"2016","journal-title":"J Pharm Sci"},{"issue":"4593","key":"10.1016\/j.vaccine.2024.01.076_b0270","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.6828890","article-title":"Formaldehyde damage to DNA and inhibition of DNA repair in human bronchial cells","volume":"220","author":"Grafstrom","year":"1983","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.076_b0275","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/074823378900500510","article-title":"Formaldehyde: an experimental multipotential carcinogen","volume":"5","author":"Soffritti","year":"1989","journal-title":"Toxicol Ind Health"},{"key":"10.1016\/j.vaccine.2024.01.076_b0280","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jim.2008.05.009","article-title":"An improved method for development of toxoid vaccines and antitoxins","volume":"337","author":"Jones","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2024.01.076_b0285","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0264-410X(95)00230-X","article-title":"The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies","volume":"14","author":"Ibsen","year":"1996","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.076_b0290","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1128\/iai.62.5.1830-1834.1994","article-title":"Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing","volume":"62","author":"di Tommaso","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2024.01.076_b0295","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1473-3099(20)30331-5","article-title":"Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial","volume":"21","author":"de Bruyn","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.076_b0300","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0264-410X(91)90289-I","article-title":"Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children","volume":"9","author":"Siber","year":"1991","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.076_b0305","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0022-3476(05)81599-9","article-title":"Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide, in 18- to 23-month-old children","volume":"116","author":"Krantz","year":"1990","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2024.01.076_b0310","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1016\/j.vaccine.2017.04.055","article-title":"Carbohydrate fatty acid monosulphate esters are safe and effective adjuvants for humoral responses","volume":"35","author":"Hilgers","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.076_b0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0094-1","article-title":"The wide utility of rabbits as models of human diseases","volume":"50","author":"Esteves","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.vaccine.2024.01.076_b0320","first-page":"499","article-title":"Rabbit models for studying human infectious diseases","volume":"65","author":"Peng","year":"2015","journal-title":"Comp Med"},{"key":"10.1016\/j.vaccine.2024.01.076_b0325","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/toxins13040240","article-title":"Systematic evaluation of parameters important for production of native toxin A and toxin B from Clostridioides difficile","volume":"13","author":"Aminzadeh","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2024.01.076_b0330","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.vaccine.2016.03.098","article-title":"Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers","volume":"34","author":"B\u00e9zay","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.076_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz153","article-title":"A phase 2 study evaluating the safety, tolerability, and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy US adults aged 65 to 85 years","volume":"70","author":"Kitchin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.076_b0340","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s40265-016-0673-1","article-title":"Bezlotoxumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2024.01.076_b0345","unstructured":"Pfizer, Phase 3 CLOVER trial for Pfizer\u2019s investigational clostridioides difficile vaccine indicates strong potential effect in reducing duration and severity of disease based on secondary endpoints. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/phase-3-clover-trial-pfizers-investigational-clostridioides; 2022."},{"key":"10.1016\/j.vaccine.2024.01.076_b0350","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.vaccine.2009.10.144","article-title":"Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)","volume":"28","author":"Leav","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.076_b0355","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2004.11.004","article-title":"Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea","volume":"128","author":"Sougioultzis","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2024.01.076_b0360","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1016\/j.vaccine.2023.10.017","article-title":"Carbohydrate fatty acid monosulphate ester is a potent adjuvant for low-dose seasonal influenza vaccines","volume":"41","author":"Platenburg","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.076_b0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170640","article-title":"Development of a novel vaccine containing binary toxin for the prevention of Clostridium difficile disease with enhanced efficacy against NAP1 strains","volume":"12","author":"Secore","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.076_b0370","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1128\/IAI.00215-12","article-title":"A chimeric toxin vaccine protects against primary and recurrent clostridium difficile infection","volume":"80","author":"Wang","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2024.01.076_b0375","first-page":"28","article-title":"Toward a structural understanding of Clostridium difficile toxins A and B","volume":"2","author":"Pruitt","year":"2012","journal-title":"Front Cell Infect Microbilol"},{"key":"10.1016\/j.vaccine.2024.01.076_b0380","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4161\/hv.24696","article-title":"The effect of aging of the immune system on vaccination responses","volume":"9","author":"Lord","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.01.076_b0385","doi-asserted-by":"crossref","first-page":"8264","DOI":"10.1016\/j.vaccine.2020.11.002","article-title":"Understanding immunosenescence and its impact on vaccination of older adults","volume":"38","author":"Allen","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.076_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.01.076_b0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/toxins13030217","article-title":"Biomarkers of deoxynivalenol toxicity in chickens with special emphasis on metabolic and welfare parameters","volume":"13","author":"Riahi","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2024.01.076_b0400","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.vaccine.2019.10.050","article-title":"Booster vaccination with a fractional dose of an oral cholera vaccine induces comparable vaccine-specific antibody avidity as a full dose: a randomised clinical trial","volume":"38","author":"Mottram","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.076_b0405","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coi.2007.10.010","article-title":"Antigen presentation by monocytes and monocyte-derived cells","volume":"20","author":"Randolph","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2024.01.076_b0410","doi-asserted-by":"crossref","DOI":"10.1084\/jem.194.9.f47","article-title":"New mechanisms and pathways for monocyte recruitment","volume":"194","author":"Muller","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2024.01.076_b0415","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1128\/IAI.73.3.1625-1634.2005","article-title":"Monocytes are highly sensitive to Clostridium difficile toxin A-induced apoptotic and nonapoptotic cell death","volume":"73","author":"Solomon","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2024.01.076_b0420","doi-asserted-by":"crossref","DOI":"10.1042\/bst0191154","article-title":"Morphological changes in adherent cells induced by Clostridium difficile toxins","volume":"19","author":"von Eichel-Streiber","year":"1991","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.vaccine.2024.01.076_b0425","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-3083.2011.02578.x","article-title":"Differential binding and internalization of Clostridium difficile toxin A by human peripheral blood monocytes, neutrophils and lymphocytes","volume":"74","author":"Modi","year":"2011","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2024.01.076_b0430","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1111\/bph.15526","article-title":"Inhaled bacteriophage therapy in a porcine model of pneumonia caused by Pseudomonas aeruginosa during mechanical ventilation","volume":"178","author":"Guillon","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.vaccine.2024.01.076_b0435","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/nmeth.2692","article-title":"ScientiFig: a tool to build publication-ready scientific figures","volume":"10","author":"Aigouy","year":"2013","journal-title":"Nat Methods"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:37:31Z","timestamp":1759405051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24001014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":87,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0264410X24001014"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.076","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}